Evidence map›Paper›PMID 32332459›Full record

Trial reportJournal of clinical psychopharmacology

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia.

Herbert Y Meltzer, Daniel B Share, Karu Jayathilake, Ronald M Salomon, Myung A Lee

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. The Importance of Stereochemistry in 5-HTACS chemical neuroscience · 2024
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Augmentation therapy with serotoninSchizophrenia research. Cognition · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Herbert Y MeltzerFrom the Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL.
Daniel B ShareFrom the Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL.
Karu JayathilakeFrom the Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL.
Ronald M SalomonDepartment of Psychiatry, University of Arkansas School of Medicine, Little Rock, AR.
Myung A LeeDepartment of Psychiatry, Vanderbilt University, School of Medicine, Nashville, TN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE/

backgroundIn addition to clozapine, other atypical antipsychotic drugs pharmacologically similar to clozapine, for example, olanzapine, risperidone, and melperone, are also effective in a similar proportion of treatment-resistant schizophrenia (TRS) patients, ~40%. The major goal of this study was to compare 2 doses of lurasidone, another atypical antipsychotic drug, and time to improvement in psychopathology and cognition during a 6-month trial in TRS patients. METHODS/PROCEDURES: The diagnosis of TRS was based on clinical history and lack of improvement in psychopathology during a 6-week open trial of lurasidone 80 mg/d (phase 1). This was followed by a randomized, double-blind, 24-week trial of lurasidone, comparing 80- and 240-mg/d doses (phase 2). FINDINGS/

resultsSignificant non-dose-related improvement in the Positive and Negative Syndrome Scale-Total and subscales and in 2 of 7 cognitive domains, speed of processing and executive function, were noted. Twenty-eight (41.8%) of 67 patients in the combined sample improved ≥20% in the Positive and Negative Syndrome Scale-Total. Of the 28 responders, 19 (67.9%) first reached ≥20% improvement between weeks 6 and 24 during phase 2, including some who had previously failed to respond to clozapine. IMPLICATIONS/

conclusionsImprovement with lurasidone is comparable with those previously reported for clozapine, melperone, olanzapine, and risperidone in TRS patients. In addition, this study demonstrated that 80 mg/d lurasidone, an effective and tolerable dose for non-TRS patients, was also effective in TRS patients but required longer duration of treatment. Direct comparison of lurasidone with clozapine in TRS patients is indicated.

Indexed as

Schizophrenic PsychologyAdultAntipsychotic AgentsDouble-Blind MethodDrug ResistanceFemaleHumansLurasidone HydrochlorideMalePsychiatric Status Rating ScalesSchizophreniaTreatment OutcomeAntipsychotic AgentsLurasidone Hydrochloride

Identifiers

PMID32332459
PMCPMC7188269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.